期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

从不同类型抗HER-2靶向治疗中双重获益的转移性乳腺癌1例

在线阅读 下载PDF
导出
摘要 两种不同类型的抗人表皮生长因子受体2（humanepidermal growth factor receptor-2,HER-2）靶向药物曲妥珠单抗（赫赛汀）及拉帕替尼显著改善了HER-2阳性转移性乳腺癌患者无进展生存期（progression-free survival,PFS）和总生存期（overall survival,OS）[1]。
作者 边莉 宋金洁 张会强 王涛 江泽飞
机构地区 军事医学科学院附属医院乳腺肿瘤科
出处 《中国癌症杂志》 CAS CSCD 北大核心 2012年第12期954-955,共2页 China Oncology
关键词 抗人表皮中长冈了受体-2 靶向治疗 曲妥珠单抗 拉帕替尼 双重获益 转移性乳腺癌
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献54

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：165
  • 2Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25 : 118-145.
  • 3Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 1987, 235 : 177-182.
  • 4Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med, 2001, 344:783- 792.
  • 5Marty M, Cognetti F, Maraninehi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23: 4265 -4274.
  • 6Papaldo P, Fabi A, Ferretti G, et al. A phase Ⅱ study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol, 2006, 17: 630-636.
  • 7Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TANDEM study. J Clin Oncol, 2009, 27:5529-5537.
  • 8von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol, 2009, 27: 1999- 2006.
  • 9Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 2008, 112:533-543.
  • 10Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353:1673-1684.

共引文献73

中国癌症杂志
2012年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部